For example, PD-1/PD-L1 checkpoint blocking greatly changed the treatment of non-small cell lung cancer (NSCLC), kidney cancer, chronic Hodgkin's lymphoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and melanoma [10–14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.